269 related articles for article (PubMed ID: 30465278)
1. Prevalence of subcutaneous implantable cardioverter-defibrillator based on template ECG screening and ineligible surface ECG predicting factors in patients with hypertrophic cardiomyopathy in China.
Guo L; Zhang M; Hu M; Wang B; Wang J; Zuo L; Yang W; Liu B; Liu L
Heart Vessels; 2019 May; 34(5):851-859. PubMed ID: 30465278
[TBL] [Abstract][Full Text] [Related]
2. Disease Severity and Exercise Testing Reduce Subcutaneous Implantable Cardioverter-Defibrillator Left Sternal ECG Screening Success in Hypertrophic Cardiomyopathy.
Srinivasan NT; Patel KH; Qamar K; Taylor A; Bacà M; Providência R; Tome-Esteban M; Elliott PM; Lambiase PD
Circ Arrhythm Electrophysiol; 2017 Apr; 10(4):. PubMed ID: 28408651
[TBL] [Abstract][Full Text] [Related]
3. Eligibility for the Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy.
Francia P; Adduci C; Palano F; Semprini L; Serdoz A; Montesanti D; Santini D; Musumeci B; Salvati A; Volpe M; Autore C
J Cardiovasc Electrophysiol; 2015 Aug; 26(8):893-899. PubMed ID: 25996259
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy.
Maurizi N; Olivotto I; Olde Nordkamp LR; Baldini K; Fumagalli C; Brouwer TF; Knops RE; Cecchi F
Heart Rhythm; 2016 Feb; 13(2):457-63. PubMed ID: 26362577
[TBL] [Abstract][Full Text] [Related]
5. How many patients fulfil the surface electrocardiogram criteria for subcutaneous implantable cardioverter-defibrillator implantation?
Randles DA; Hawkins NM; Shaw M; Patwala AY; Pettit SJ; Wright DJ
Europace; 2014 Jul; 16(7):1015-21. PubMed ID: 24351884
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
Weinstock J; Bader YH; Maron MS; Rowin EJ; Link MS
J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873684
[TBL] [Abstract][Full Text] [Related]
7. Which patients are not suitable for a subcutaneous ICD: incidence and predictors of failed QRS-T-wave morphology screening.
Olde Nordkamp LRA; Warnaars JLF; Kooiman KM; de Groot JR; Rosenmöller BRAM; Wilde AAM; Knops RE
J Cardiovasc Electrophysiol; 2014 May; 25(5):494-499. PubMed ID: 24320684
[TBL] [Abstract][Full Text] [Related]
8. Predictors of electrocardiographic screening failure for the subcutaneous implantable cardioverter-defibrillator in children: A prospective multicenter study.
Campbell M; Moore JP; Sreeram N; von Alvensleben JC; Shah A; Batra A; Law I; Sanatani S; Thomas V; Nik-Ahd F; Williams S; Nosavan N; Maldonado J; Hart A; Nguyen T; Balaji S
Heart Rhythm; 2018 May; 15(5):703-707. PubMed ID: 29309839
[TBL] [Abstract][Full Text] [Related]
9. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.
Nazer B; Dale Z; Carrassa G; Reza N; Ustunkaya T; Papoutsidakis N; Gray A; Howell SJ; Elman MR; Pieragnoli P; Ricciardi G; Jacoby D; Frankel DS; Owens A; Olivotto I; Heitner SB
Heart Rhythm; 2020 Jul; 17(7):1107-1114. PubMed ID: 32084597
[TBL] [Abstract][Full Text] [Related]
10. Conventional and alternative preimplantation ECG screening for subcutaneous ICD in high risk hypertrophic cardiomyopathy patients.
Kaczmarek K; Kałowski M; Krzysztof Wranicz J; Ptaszyńsk P; Cygankiewicz I
J Electrocardiol; 2020; 58():68-73. PubMed ID: 31770668
[TBL] [Abstract][Full Text] [Related]
11. Eligibility for subcutaneous implantable cardioverter-defibrillator in congenital heart disease.
Wang L; Javadekar N; Rajagopalan A; Rogovoy NM; Haq KT; Broberg CS; Tereshchenko LG
Heart Rhythm; 2020 May; 17(5 Pt B):860-869. PubMed ID: 32354451
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts.
Lambiase PD; Gold MR; Hood M; Boersma L; Theuns DAMJ; Burke MC; Weiss R; Russo AM; Kääb S; Knight BP
Heart Rhythm; 2016 May; 13(5):1066-1074. PubMed ID: 26767422
[TBL] [Abstract][Full Text] [Related]
13. The T-peak-to-T-end interval: a novel ECG marker for ventricular arrhythmia and appropriate ICD therapy in patients with hypertrophic cardiomyopathy.
Dinshaw L; Münch J; Dickow J; Lezius S; Willems S; Hoffmann BA; Patten M
Clin Res Cardiol; 2018 Feb; 107(2):130-137. PubMed ID: 28965260
[TBL] [Abstract][Full Text] [Related]
14. Impact of routine right parasternal electrocardiographic screening in assessing eligibility for subcutaneous implantable cardioverter-defibrillator.
Arias MA; Pachón M; Sánchez-Iglesias I; Loughlin G; Martín-Sierra C; Puchol A; Sabatel F; Rodríguez-Padial L
J Cardiovasc Electrophysiol; 2020 Jan; 31(1):103-111. PubMed ID: 31724763
[TBL] [Abstract][Full Text] [Related]
15. Use of an electrocardiographic screening tool to determine candidacy for a subcutaneous implantable cardioverter-defibrillator.
Groh CA; Sharma S; Pelchovitz DJ; Bhave PD; Rhyner J; Verma N; Arora R; Chicos AB; Kim SS; Lin AC; Passman RS; Knight BP
Heart Rhythm; 2014 Aug; 11(8):1361-6. PubMed ID: 24755323
[TBL] [Abstract][Full Text] [Related]
16. The utility of routine clinical 12-lead ECG in assessing eligibility for subcutaneous implantable cardioverter defibrillator.
Thomas JA; Perez-Alday EA; Hamilton C; Kabir MM; Park EA; Tereshchenko LG
Comput Biol Med; 2018 Nov; 102():242-250. PubMed ID: 29754992
[TBL] [Abstract][Full Text] [Related]
17. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.
Maron BJ; Casey SA; Olivotto I; Sherrid MV; Semsarian C; Autore C; Ahmed A; Boriani G; Francia P; Winters SL; Giudici M; Koulova A; Garberich R; Rowin EJ; Sears SF; Maron MS; Spirito P
Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e005820. PubMed ID: 29625970
[TBL] [Abstract][Full Text] [Related]
18. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
Syska P; Przybylski A; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Gepner K; Pytkowski M; Kowalik I; Maczyńska-Mazuruk R; Ruzyłło W; Szwed H
J Cardiovasc Electrophysiol; 2010 Aug; 21(8):883-9. PubMed ID: 20132378
[TBL] [Abstract][Full Text] [Related]
19. Eligibility of Pacemaker Patients for Subcutaneous Implantable Cardioverter Defibrillators.
Ip JE; Wu MS; Kennel PJ; Thomas G; Liu CF; Cheung JW; Markowitz SM; Lerman BB
J Cardiovasc Electrophysiol; 2017 May; 28(5):544-548. PubMed ID: 28185354
[TBL] [Abstract][Full Text] [Related]
20. Exercise stress test reveals ineligibility for subcutaneous implantable cardioverter defibrillator in patients with Brugada syndrome.
Tachibana M; Nishii N; Morita H; Nakagawa K; Watanabe A; Nakamura K; Ito H
J Cardiovasc Electrophysiol; 2017 Dec; 28(12):1454-1459. PubMed ID: 28800177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
